Measuring the Return From Pharmaceutical Innovation: Be Brave, Be Bold New Insights & Webinar Invitation
Research and development innovation is the lifeblood of the pharmaceutical sector but in a highly competitive market returns are hard won. Our 15th annual detailed analysis, in Measuring the return from pharmaceutical innovation: Be brave, be bold, shows an upward trajectory with the IRR increasing from 4.3% in 2023 to 5.9% in 2024. This positive trend is driven largely by new high-value blockbuster assets entering the late-stage pipeline, particularly for therapies addressing obesity, menopause, Alzheimer’s, and other unmet needs.